LABCORP Abstract: While adoption/acceptance/use of Mobile Clinical Services (MCS) is growing /increasing in most regions around the world, a number of Asia-Pacific countries remain hesitant to commit to this new approach to clinical trials. This case study reviews Labcorp MCS support of a global pulmonary inflammation clinical trial that was active in Australia, highlighting the benefits on a global level and the specific challenges faced in the Pacific country.
Leave a Comment